Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week

[Reuters] – Amgen’s new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Repatha, or . . . → Read More: Market Update (NASDAQ:AMGN): Amgen cholesterol drug could get EU green light this week Similar Articles: Stock Update (NASDAQ:AMGN): U.S. FDA approves Amgen heart failure drug Company Update (NASDAQ:AMGN): Amgen to appeal rejection of bid to block Novartis biosimilar drug Stock Update: AbbVie Inc (NYSE:ABBV) – Europe gives green light to AbbVie hepatitis C medicine, others